OOIR: Observatory of International Research

Papers

(The H4-Index of Rheumatology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	122
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	89
Boxer’s shape, an unusual finding in nailfold capillaroscopy	83
Giant cell arteritis of the prostate	67
Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up	63
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	63
Editor’s Acknowledgement	60
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	57
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	56
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	53
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	51
Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease	50
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	49
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	48
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	47
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	47
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study	47
Haematologic malignancy-associated mucocutaneous paraneoplastic syndrome	47
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	45
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	44
The role of IL-23 in joint disease	43
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	42
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	42
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	41
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	41

Annular erythematous plaques as manifestation of vasculitis in pediatric Sjögren’s syndrome	41
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	40
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	40
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	40
Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis	38
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	38
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?	38
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	38
VEXAS syndrome mimicking lupus-like disease	37
Bezoar secondary to NSAID use in a patient with inflammatory arthritis	37
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study	36
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients	36